{"issuance_frequency":"","notes_translated":{"fr":"\"Parmi les espèces de bacilles Gram négatif les plus courantes dans les établissements de soins de santé, on compte Pseudomonas aeruginosa, Acinetobacter spp. et Stenotrophomonas maltophilia, ainsi que des espèces appartenant à la famille des Enterobacteriaceae, comme Escherichia coli, Klebsiella pneumoniae et Enterobacter cloacae. Certains événements récents indiquent que la résistance des bactéries Gram négatif aux antimicrobiens est de plus en plus fréquente. Les antimicrobiens du groupe des carbapénèmes sont un traitement sécuritaire et généralement efficace contre les infections bactériennes Gram négatif lorsque la résistance aux autres classes d'antimicrobiens est présente. Lorsque les bactéries sont résistantes aux carbapénèmes, il y a souvent peu de traitements de rechange d'offerts. La résistance aux carbapénèmes des bactéries Gram négatif peut être due à divers mécanismes. L'identification de la résistance aux carbapénèmes et l'établissement d'une distinction entre les différents mécanismes de résistance peuvent être difficiles pour les laboratoires de microbiologie clinique. La résistance aux carbapénèmes est le résultat de la production d'enzymes hydrolisant le carbapénème. Ces enzymes sont normalement codées par des gènes qui se retrouvent sur des éléments génétiques mobiles, comme les plasmides, lesquels peuvent rapidement se transmettre à des genres de bactéries apparentés. Voici des exemples notables de carbapénémase récemment observés :\r\n•Carbapénémase Klebsiella pneumoniae carbapenemase (KPC), observée principalement dans la bactérie K. pneumoniae, mais aussi dans d'autres Enterobacteriaceae. Les microorganismes producteurs de la carbapénémase KPC ont causé d'importantes éclosions liées aux soins de santé en Grèce, en Israël et dans le nord-est des États-Unis;\r\n•Gènes de résistance de type OXA trouvés dans Acinetobacter spp. L'Acinetobacter résistant aux carbapénèmes a été observé partout dans le monde, mais il est peu fréquent dans les hôpitaux canadiens à l'heure actuelle.\r\n•Métallo-ß-lactamases trouvées principalement dans P. aeruginosa et Acinetobacter spp., mais rarement dans d'autres Enterobacteriaceae,notamment la New Delhi métallo-bêta-lactamase (enzyme NDM-1), trouvée dans Escherichia coli et K. pneumoniae, et aussi dans d'autres Enterobacteriaceae. La New Delhi métallo-bêta-lactamase (enzyme NDM-1) a récemment été observée en Inde et au Pakistan et chez des patients hospitalisés dans d'autres pays ayant reçu des soins de santé en Inde ou au Pakistan.\r\n\"\r\n","en":"\"Gram-negative bacilli commonly encountered in healthcare settings include species such as Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia, and species belonging to the Enterobacteriaceae family, such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. Recent events indicate an increasing occurrence of antimicrobial resistance in Gram-negative bacteria. The carbapenem group of antimicrobials is a safe and generally effective treatment for severe Gram-negative bacterial infections when resistance to other classes of antimicrobials is present. When resistance to carbapenems occurs, there are often few alternative treatments available. Carbapenem-resistance in Gram-negative bacteria can occur by a number of different mechanisms. Identifying carbapenem resistance and distinguishing between these different mechanisms of resistance can be challenging for clinical microbiology laboratories. Carbapenem resistance develops as a result of the production of carbapenem-hydrolysing enzymes. These enzymes are usually encoded by genes carried on mobile genetic elements such as plasmids which can rapidly spread amongst related bacterial genera. Some notable examples of recently identified carbapenemases are:\r\n•Klebsiella pneumoniae carbapenemase (KPC) which is found mostly in K. pneumoniae but also in other Enterobacteriaceae. KPC producing microorganisms have caused major healthcare related outbreaks in Greece, Israel and north eastern USA;\r\n•The OXA-type resistance genes found in Acinetobacter spp. Carbapenem-resistant Acinetobacter has been identified worldwide but is currently rarely seen in Canadian hospitals.\r\n•Metallo-ß-lactamases which are mostly found in P. aeruginosa and Acinetobacter spp., and rarely in other Enterobacteriaceae; and include the New Delhi metallo beta-lactamase (NDM-1 enzyme) found mostly in Escherichia coli and K. pneumoniae, but also seen in other Enterobacteriaceae. The New Delhi metallo beta-lactamase (NDM-1 enzyme) has recently been identified in India and Pakistan and in patients hospitalized in other countries after receiving health care in India and Pakistan.\r\n\"\r\n"},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"unknown","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"73f22d5b-4221-4019-8ad8-0ca4f3607593","metadata_created":"2018-12-13T18:40:57.914240","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2018-12-13T18:40:57.914249","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2018-12-13","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["soins","santé","patients","transmission","précautions","établissement","laboratoire","nettoyage","environnement","résistance"],"en":["patients","contact","precautions","infection","healthcare","laboratory","resistance","cleaning","organization","testing","health"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"Lignes directrices :  Mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé","en":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"73f22d5b-4221-4019-8ad8-0ca4f3607593","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9e301f2c-e8bc-4d75-8e13-f47f04b081f6","related_relationship":"","name_translated":{"fr":"Lignes directrices :  Mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé","en":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings","language":["en"],"created":"2018-12-13T18:40:59.185773","url":"https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/nois-sinp/guide/ipcm-mpci/pdf/guide-eng.pdf","last_modified":null,"position":0,"revision_id":"a7556b07-2b0d-4fda-aa8c-0ede10b543f1","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"73f22d5b-4221-4019-8ad8-0ca4f3607593","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"faeb03bc-2872-43b3-92e5-6798a4905cc1","related_relationship":"","name_translated":{"fr":"Lignes directrices :  Mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé","en":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings","language":["fr"],"created":"2018-12-13T18:40:59.185781","url":"https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/nois-sinp/guide/ipcm-mpci/pdf/guide-fra.pdf","last_modified":null,"position":1,"revision_id":"a7556b07-2b0d-4fda-aa8c-0ede10b543f1","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"73f22d5b-4221-4019-8ad8-0ca4f3607593","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"43886eea-be87-4482-87a0-c7d6d1213a49","related_relationship":"","name_translated":{"fr":"Lignes directrices :  Mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé","en":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings","language":["en"],"created":"2018-12-13T18:40:59.185784","url":"https://www.canada.ca/en/public-health/services/infectious-diseases/nosocomial-occupational-infections/guidance-infection-prevention-control-measures-healthcare-workers-healthcare-settings.html","last_modified":null,"position":2,"revision_id":"a7556b07-2b0d-4fda-aa8c-0ede10b543f1","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"73f22d5b-4221-4019-8ad8-0ca4f3607593","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"fcaad304-b3c7-40da-a8b9-1f8aa9df9255","related_relationship":"","name_translated":{"fr":"Lignes directrices :  Mesures de prévention et de contrôle des infections à l'intention des travailleurs de la santé dans tous les établissements de soins de santé","en":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings","language":["fr"],"created":"2018-12-13T18:40:59.185786","url":"https://www.canada.ca/fr/sante-publique/services/maladies-infectieuses/infections-nosocomiales-professionnelles/lignes-directrices-mesures-prevention-controle-infections-a-intention-travailleurs-sante-tous-etablissements-soins-sante.html","last_modified":null,"position":3,"revision_id":"a7556b07-2b0d-4fda-aa8c-0ede10b543f1","resource_type":"website"}],"place_of_publication":[],"num_resources":4,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2012-04-03 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"73f22d5b-4221-4019-8ad8-0ca4f3607593","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"\"Gram-negative bacilli commonly encountered in healthcare settings include species such as Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia, and species belonging to the Enterobacteriaceae family, such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. Recent events indicate an increasing occurrence of antimicrobial resistance in Gram-negative bacteria. The carbapenem group of antimicrobials is a safe and generally effective treatment for severe Gram-negative bacterial infections when resistance to other classes of antimicrobials is present. When resistance to carbapenems occurs, there are often few alternative treatments available. Carbapenem-resistance in Gram-negative bacteria can occur by a number of different mechanisms. Identifying carbapenem resistance and distinguishing between these different mechanisms of resistance can be challenging for clinical microbiology laboratories. Carbapenem resistance develops as a result of the production of carbapenem-hydrolysing enzymes. These enzymes are usually encoded by genes carried on mobile genetic elements such as plasmids which can rapidly spread amongst related bacterial genera. Some notable examples of recently identified carbapenemases are:\r\n•Klebsiella pneumoniae carbapenemase (KPC) which is found mostly in K. pneumoniae but also in other Enterobacteriaceae. KPC producing microorganisms have caused major healthcare related outbreaks in Greece, Israel and north eastern USA;\r\n•The OXA-type resistance genes found in Acinetobacter spp. Carbapenem-resistant Acinetobacter has been identified worldwide but is currently rarely seen in Canadian hospitals.\r\n•Metallo-ß-lactamases which are mostly found in P. aeruginosa and Acinetobacter spp., and rarely in other Enterobacteriaceae; and include the New Delhi metallo beta-lactamase (NDM-1 enzyme) found mostly in Escherichia coli and K. pneumoniae, but also seen in other Enterobacteriaceae. The New Delhi metallo beta-lactamase (NDM-1 enzyme) has recently been identified in India and Pakistan and in patients hospitalized in other countries after receiving health care in India and Pakistan.\r\n\"\r\n","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance: Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings","revision_id":"a7556b07-2b0d-4fda-aa8c-0ede10b543f1"}